Join to View Full Profile
533 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2739
Dr. Carnevale is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 2011 - 2014
Harvard Medical SchoolClass of 2011- University of California (San Francisco)Fellowship, Hematology and Medical Oncology
Certifications & Licensure
CA State Medical License 2013 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsCentral control of dynamic gene circuits governs T cell rest and activation.Maya M Arce, Jennifer M Umhoefer, Nadia Arang, Sivakanthan Kasinathan, Jacob W Freimer
Nature. 2025-01-01 - Cellular behavior analysis from live-cell imaging of TCR T cell-cancer cell interactions.Archit Verma, Changhua Yu, Stefanie Bachl, Ivan Lopez, Morgan Schwartz
Biorxiv. 2024-11-21 - 21 citationsModular pooled discovery of synthetic knockin sequences to program durable cell therapies.Franziska Blaeschke, Yan Yi Chen, Ryan Apathy, Bence Daniel, Andy Y Chen
Cell. 2023-09-14
Journal Articles
- Reprogramming Human T Cell Function and Specificity with Non-Viral Genome TargetingNeil Romberg, Antoni Ribas, Michael R Lee, Ruby Yu, Gary M Kupfer, Julia Carnevale, Jonathan H Esensten, P Jonathan Li, Han Li, Kevan C Herold, Alexander Marson, Nature
Press Mentions
Scientists Prevent 'Exhaustion' in Cancer-Fighting T CellsJune 28th, 2022
New Immunotherapy Brings Hope in Fight Against Fatal CancersNovember 16th, 2018
New 'SLICE' Tool Can Massively Expand Immune System's Cancer-Fighting RepertoireNovember 15th, 2018- Join now to see all
Grant Support
- Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
